Investigational drug · Phase 2
E2814
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "E2814"
First trial start
2024
Sep 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "E2814", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer's Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "E2814" as an intervention, largest first.
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001Pivotal-lookingActive, not recruiting
Washington University School of MedicineAcademic, hospital or other
NCT01760005 · 490 participants (planned) · Start Dec 2012 · Primary completion Apr 2028
Drug: Gantenerumab; Solanezumab and 6 more · For: Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 38 sites in all
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)Pivotal-lookingActive, not recruiting
Washington University School of MedicineAcademic, hospital or other
NCT05269394 · 197 participants · Start Dec 22, 2021 · Primary completion Apr 2028
Drug: E2814; Lecanemab and 1 more · For: Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 31 sites in all
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseasePivotal-lookingActive, not recruiting
Eisai Inc.Eisai
NCT06602258 · 105 participants · Start Sep 30, 2024 · Primary completion Dec 3, 2026
Drug: E2814; Lecanemab and 1 more · For: Alzheimer's Disease
Sites: Phoenix, Arizona; New Haven, Connecticut; Bradenton, Florida · 26 sites in all
Eisai Inc.Eisai
NCT04231513 · 72 participants · Start Dec 16, 2019 · Primary completion Mar 9, 2023
Drug: E2814; E2814-matched placebo · For: Healthy Volunteers
Sites: Glendale, California; San Antonio, Texas
Eisai Inc.Eisai
NCT04971733 · 8 participants · Start Jun 28, 2021 · Primary completion May 24, 2024
Drug: E2814 · For: Alzheimer Disease
Sites: La Jolla, California; Indianapolis, Indiana; London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- A validated ligand binding assay for the determination of etalanetug, a novel anti-tau therapeutic antibody, in rats and monkeys for nonclinical pharmacokinetic studies.
Aoyama M, Noritake Y, Kita K, et al. · J Pharm Biomed Anal 2026
- Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment.
Andreozzi E, Yagi T, Wildsmith K, et al. · Alzheimers Res Ther 2026
- From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials.
Verma M, Singh NK · Metab Brain Dis 2026
- An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects.
Rawal S, Wildsmith KR, Aluri J, et al. · Alzheimer Dis Assoc Disord 2025
- Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species.
Siebrand CJ, Bergo NJ, Lee S, et al. · J Transl Med 2025
- Chimeric Antigen Receptors Discriminate Between Tau and Distinct Amyloid-Beta Species.
Siebrand CJ, Bergo NJ, Lee S, et al. · bioRxiv 2025
Also in development for Alzheimer's Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- TrontinemabRO7126209, RG6102Phase 34 trials
Roche (Genentech) · Alzheimers Disease, Alzheimer's Disease
- [18F]-APN-1607Phase 32 trials
JYAMS PET Research & Development Limited · Alzheimer's Disease, Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
- RemternetugLY3372993Phase 31 trial
Eli Lilly · Alzheimer's Disease
- RO7568282Phase 22 trials
Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease
- VHB937Phase 22 trials
Novartis · Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease
- ABBV-1758Phase 21 trial
AbbVie · Alzheimer's Disease
- GSK4527226Phase 21 trial
GSK · Alzheimer's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eisai.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.